Blue Dye 2 vs Neotame: which is worse?

What is Blue Dye 2?

Blue Dye 2 (Indigotine/Indigo Carmine) is a synthetic disulfonated derivative of indigo. Unlike natural indigo from the indigo plant, the FD&C version is synthetically manufactured from petroleum. It produces a dark royal blue to indigo color and is used in food, pharmaceuticals, and medical diagnostics.

What is Neotame?

Neotame is a synthetic dipeptide sweetener — a derivative of aspartame with a 3,3-dimethylbutyl group added to block aspartame's metabolism, preventing the release of phenylalanine. This means it is safe for people with phenylketonuria (PKU), unlike aspartame. It is approximately 7,000-13,000 times sweeter than sucrose.

Documented risks

Blue Dye 2: Animal studies conducted in the 1980s found that high-dose Blue Dye 2 caused brain tumors in male rats. An NTP bioassay (1987) found statistically significant increases in brain gliomas (astrocytomas) in male rats given high doses. The FDA reviewed these findings and determined that the doses far exceeded typical human dietary exposure. Nonetheless, the tumor finding remains in the scientific record as a concerning data point. EFSA's 2010 safety evaluation of Indigo Carmine (E132) reached an unusual conclusion: it could not establish an ADI due to data limitations, including the brain tumor findings. This means EFSA adopted an implicit conservative position — it neither declared Blue 2 safe nor formally banned it, but the absence of an established ADI signals scientific uncertainty. In medical diagnostic use, high intravenous doses of Indigo Carmine can cause hypertension, bradycardia, and in rare cases anaphylaxis. These are dose-specific clinical pharmacological effects, not relevant to dietary consumption at food use levels. Blue 2 was not included in the 2007 Lancet hyperactivity study. Limited direct research links Blue 2 to behavioral effects. The FDA's April 2025 announcement includes Blue 2 in the class of petroleum-based synthetic dyes to be phased out of the US food supply, reflecting updated policy on the category rather than specific new Blue 2 toxicity data.

Neotame: Neotame is one of the newer synthetic sweeteners with a shorter safety track record. A 2023 study published in Frontiers in Nutrition found that neotame damaged intestinal epithelial cells in vitro and disrupted the gut microbiome in mice — including reducing beneficial bacteria and increasing bacterial invasion of intestinal cells. The study observed effects at concentrations that could be achievable through high consumption of neotame-containing products. The FDA has set an ADI of 0.3 mg/kg/day, one of the lower sweetener ADIs, reflecting a conservative safety margin. Limited long-term human safety data exist compared to aspartame, acesulfame K, or saccharin, which have been used for decades. EFSA's 2010 opinion found no safety concern at permitted levels. The Frontiers in Nutrition 2023 gut study represents new concerning findings that warrant further investigation.